Key Points
- Ra Capital Management executed a multiday selling spree, disposing of a total of 540,277 shares of Sionna between Oct. 24 and Nov. 21 for roughly $21.5 million; after the Nov. 20 sale it still owned 166,642 shares (the Nov. 20 trade reduced its position by 2.99%).
- Sionna is trading near its 12‑month high (opened $44.38, 12‑month high $45.00) with a market cap of $1.98 billion and a negative PE (-9.11), and its 50- and 200-day SMAs are $33.19 and $23.59 respectively.
- Analyst sentiment is mixed but overall rated a Moderate Buy with an average target of $40.00, and the company recently reported quarterly EPS of ($0.46), beating estimates of ($0.52).
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Ra Capital Management, L.P. sold 5,133 shares of the firm's stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $40.13, for a total value of $205,987.29. Following the completion of the sale, the director directly owned 166,642 shares in the company, valued at $6,687,343.46. This trade represents a 2.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Friday, November 21st, Ra Capital Management, L.P. sold 25,183 shares of Sionna Therapeutics stock. The shares were sold at an average price of $39.50, for a total value of $994,728.50.
- On Wednesday, November 19th, Ra Capital Management, L.P. sold 47,442 shares of Sionna Therapeutics stock. The stock was sold at an average price of $40.01, for a total transaction of $1,898,154.42.
- On Tuesday, November 18th, Ra Capital Management, L.P. sold 6,922 shares of Sionna Therapeutics stock. The shares were sold at an average price of $39.57, for a total transaction of $273,903.54.
- On Monday, November 17th, Ra Capital Management, L.P. sold 81,987 shares of Sionna Therapeutics stock. The shares were sold at an average price of $40.59, for a total transaction of $3,327,852.33.
- On Tuesday, October 28th, Ra Capital Management, L.P. sold 62,610 shares of Sionna Therapeutics stock. The stock was sold at an average price of $39.58, for a total transaction of $2,478,103.80.
- On Friday, October 24th, Ra Capital Management, L.P. sold 311,000 shares of Sionna Therapeutics stock. The stock was sold at an average price of $39.50, for a total transaction of $12,284,500.00.
Sionna Therapeutics Stock Performance
NASDAQ SION opened at $44.38 on Tuesday. The firm has a 50-day simple moving average of $33.19 and a 200 day simple moving average of $23.59. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $45.00. The stock has a market cap of $1.98 billion and a PE ratio of -9.11.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06.
Hedge Funds Weigh In On Sionna Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SION. TD Asset Management Inc acquired a new stake in shares of Sionna Therapeutics during the first quarter worth approximately $579,000. Charles Schwab Investment Management Inc. acquired a new stake in Sionna Therapeutics during the 1st quarter valued at $676,000. CenterBook Partners LP bought a new position in Sionna Therapeutics in the 1st quarter valued at $1,195,000. Aberdeen Group plc acquired a new position in Sionna Therapeutics in the first quarter worth $7,803,000. Finally, Atlas Venture Life Science Advisors LLC bought a new stake in shares of Sionna Therapeutics during the first quarter worth $38,639,000.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the company. BTIG Research started coverage on Sionna Therapeutics in a research note on Wednesday, November 19th. They issued a "buy" rating and a $50.00 target price for the company. Wall Street Zen cut shares of Sionna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 15th. Jones Trading assumed coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They set a "buy" rating and a $46.00 target price on the stock. Raymond James Financial reissued a "strong-buy" rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada started coverage on shares of Sionna Therapeutics in a research note on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.00.
View Our Latest Stock Analysis on SION
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
